ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014
Revitalizing psychiatric therapeutics.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Adolescent brain development and depression: A case for the importance of connectivity of the anterior cingulate cortex.Neuroscience and biobehavioral reviews · 2016Pooled it
- Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia.Molecular psychiatry · 2015Trial
- Model Systems infrastructure of the German Center for Mental Health (DZPG): toward an integrated, mechanism-based framework for mental health research.European archives of psychiatry and clinical neuroscience · 2026Review
- Multimodal Behavior Scoring Quantifies Depression-like Severity Across Chronic Stress Models and Identifies Stress-Resilient Mice.NeuroSci · 2026Article
- Filtering the noise: a cerebellar-centered framework for understanding and treating mental illness -a paradigm shift in psychiatry.Frontiers in psychiatry · 2026Article
- Ketamine Evokes Acute Behavioral Effects Via μ Opioid Receptor-Expressing Neurons of the Central Amygdala.Biological psychiatry · 2025Article
- Therapeutic mechanisms of psychedelics and entactogens.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Understanding anxiety symptoms as aberrant defensive responding along the threat imminence continuum.Neuroscience and biobehavioral reviews · 2023Review
- Revisiting the seven pillars of RDoC.BMC medicine · 2022Article
- A translational perspective on the anti-anhedonic effect of ketamine and its neural underpinnings.Molecular psychiatry · 2022Review
- Neurobiological effects of a probiotic-supplemented diet in chronically stressed male Long-Evans rats: Evidence of enhanced resilience.IBRO neuroscience reports · 2021Article
- Neural circuit function redundancy in brain disorders.Current opinion in neurobiology · 2021Review
- Concordant neurophysiological signatures of cognitive control in humans and rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- Population Modelling in Affective Disorders.Current behavioral neuroscience reports · 2021Review
- Redirecting the revolution: new developments in drug development for psychiatry.Expert opinion on drug discovery · 2019Article
- Developing neuroscience-based treatments for alcohol addiction: A matter of choice?Translational psychiatry · 2019Review
- Glutamate diffusion in the rat brain in vivo under light and deep anesthesia conditions.Magnetic resonance in medicine · 2019Article
- Comparative Principles for Next-Generation Neuroscience.Frontiers in behavioral neuroscience · 2019Article
- Cortisol and Major Depressive Disorder-Translating Findings From Humans to Animal Models and Back.Frontiers in psychiatry · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite high prevalence and enormous unmet medical need, the pharmaceutical industry has recently de-emphasized neuropsychiatric disorders as 'too difficult' a challenge to warrant major investment. Here I describe major obstacles to drug discovery and development including a lack of new molecular targets, shortcomings of current animal models, and the lack of biomarkers for clinical trials. My major focus, however, is on new technologies and scientific approaches to neuropsychiatric disorders that give promise for revitalizing therapeutics and may thus answer industry's concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.